COMMUNIQUÉS West-GlobeNewswire

-
Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
23/05/2025 -
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
24/05/2025 -
BioSig Technologies, Inc. Signs Definitive Share Exchange Agreement with Streamex Exchange Corp. to Launch First-Mover Real-World Asset (RWA) Tokenization Company Bringing Commodity Markets On-Chain.
24/05/2025 -
Cross Medical Group Introduces HydraFacial Treatments for Advanced Skin Rejuvenation
23/05/2025 -
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
23/05/2025 -
Boundless Bio Announces Portfolio Prioritization and Runway Extension
23/05/2025 -
Mind Body Peak Performance Rebrands to ‘High Performance Longevity’ Podcast, Integrating Biohacking with Ancestral Wisdom
23/05/2025 -
Transactions of Managers and Closely Associated Persons
23/05/2025 -
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.
23/05/2025 -
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
23/05/2025 -
Sol-Gel Reports First Quarter 2025 Results
23/05/2025 -
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
23/05/2025 -
Major shareholder notification – BlackRock, Inc.
23/05/2025 -
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
23/05/2025 -
Safe Shot to Capitalize on Yerbae’s Strong Retail Presence & Distributor Network Following Acquisition
23/05/2025 -
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
23/05/2025 -
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
23/05/2025 -
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
23/05/2025 -
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
23/05/2025
Pages